Stock Ratings / Health Care / SNOA / earnings

INBS (38) TNON (43) WOK (54) NVNO (50) ⌘ Pro Terminal →

Sonoma Pharmaceuticals Inc. (SNOA) Next Earnings Date & Expected ±12.2% Move

$1.20 +5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.21

Sonoma Pharmaceuticals Inc. (SNOA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $5.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.21 (+0.76%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNOA)Realized 20D OHLCV Swing Band: ±12.2%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY SNOA SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.2% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.23-8.9% Next Q

Q2 (-2Q)

Grade D$1.12-0.9% Next Q

Q3 (-1Q)

Grade D$1.11+8.1% Next Q

Current

Grade D$1.20-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNOA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNOA currently carries a cautious 44/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.24) and Max Pain ($1.26) forces dealer call-delta covering toward $4.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNOA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.2% Swing Band

±$0.15 Expected Swing

MODEL EARNINGS SETUP GAUGE

SNOA Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 36.7%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-03-31	$19.5M	$3.2K	-$4.1M	38%
FY 2024	2025-03-31	$14.3M	$3.5K	-$168.0K	38.2%
FY 2023	2024-03-31	$12.7M	$4.8K	-$2.4M	38%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNOA)

✓Walkthrough of SNOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.09%▲ ASCENDING CHANNEL

2026-10-30O $1.16H $1.20L $1.07C $1.20VOL 85.8K

RES: $1.63SUP: $1.11SMA50: $1.24SMA200: $1.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNOA Butterfly Map → + Track SNOA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +36.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNOA)

Health Care Rank #530 of 1016 ⚔️ INBS vs SNOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNOA vs. INBS, TNON, WOK, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sonoma Pharmaceuticals Inc. (SNOA) ranks #530 by composite RQD confidence (44/100, grade D) and #932 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SNOA leads on earnings valuation at N/A trailing P/E, while SNOA leads on capital efficiency and profitability with -35.0% ROIC and 38.0% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SNOA at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNOA ACTIVE Sonoma Pharmaceuticals Inc.	D	44/100	—	38.0%	-35.0%	+5.26%	$5.7M	Benchmark Subject
INBS Intelligent Bio Solutions Inc.	D-	38/100	—	40.8%	-35.0%	+9.58%	$6.1M	/inbs-vs-snoa →
TNON Tenon Medical Inc.	D-	43/100	—	59.8%	-35.0%	+1.33%	$6.2M	/tnon-vs-snoa →
WOK WORK Medical Technology Group LTD (Class A)	D+	54/100	—	—	—	-4.35%	$4.9M	/wok-vs-snoa →
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-snoa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001367083

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported GAAP revenue of $19.5M (+36.7% vs. FY2024 revenue of $14.3M , and +53.3% cumulative change since FY2023) , GAAP net income of $3.2K, operating cash flow of -$3.9M, and free cash flow of -$4.1M (-2355.4% YoY). On the balance sheet, SNOA closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$19.5M	$3.2K	-$3.9M	-$4.1M	$13.6M	—
FY2024 (FY)	2025-03-31	$14.3M	$3.5K	-$88.0K	-$168.0K	$13.7M	—
FY2023 (FY)	2024-03-31	$12.7M	$4.8K	-$2.4M	-$2.4M	—	—

3. SNOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.20 (+5.26% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, SNOA ranks #530 in composite RQD confidence.

How does SNOA compare to INBS and TNON in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, INBS (Intelligent Bio Solutions Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M) and TNON (Tenon Medical Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNOA?

Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNOA trading relative to its 50-day, 200-day, and 52-week technical levels?

SNOA last traded at $1.20 (+5.26% on volume of 20,739 shares), positioning the stock -3.23% below its 50-day simple moving average ($1.24) and -29.41% below its 200-day simple moving average ($1.70). Across its 52-week range of $0.85 to $3.97, SNOA sits at the 11.2% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($1.05 to $1.35).

SNOA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SNOA's next earnings date?

Based on SEC filing cadence, Sonoma Pharmaceuticals Inc. (SNOA)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is SNOA stock expected to move on earnings?

Volatility modeling currently projects a ±12.2% event move for SNOA, spanning a range between $1.05 and $1.35.

Direct Sub-Reports: SNOA RQD Cockpit SNOA 12M Forecast SNOA Earnings & Move SNOA Dividends & DRIP SNOA Insiders & 13F SNOA Whale Options SNOA Profit Sankey SNOA News & Why